Video

Dr. Whitman on Improving Precision Medicine in Oncology

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.

Physicians have to do a better job of classifying patients upfront, says Whitman. Whitman believes this will come from better understanding of the genetics of the tumor and the immune system as well as their overall interaction. This will enable physicians to make the best treatment decisions, says Whitman.

As part of Atlantic Health’s partnership with Origin and TGen, physicians are going to leverage the laboratory and technical abilities of TGen to identify the patients who should be treated and those who should avoid a specific therapy. Additionally, physicians have to be able to monitor a patient beyond what the size of their lesion is on their CAT scan. This may be through subtle changes in a patient’s immune system that can be identified through testing of the tumor. This will manifest in more efficient means of identifying whether a therapy is working or not, says Whitman.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center